摘要
目的分析硝苯地平缓释片(简称NFP)与依那普利片(简称Ena)治疗原发性高血压(简称EH)的疗效及安全性。方法该研究对象为方便选取2018年1月—2019年2月间来院治疗的98例EH患者。以单双号法为标准,A组51例予以NEP+Ena治疗;B组47例予以常规治疗。对比整体疗效和用药安全性。结果A组的总有效率为96.08%,B组为80.85%,差异有统计学意义(χ^(2)=5.692,P=0.017)。治疗前,A组的收缩压(SBP)为(162.35±20.65)mmHg,B组为(163.08±20.19)mmHg,差异无统计学意义(t=0.177,P=0.860);A组的舒张压(DBP)为(103.68±11.68)mmHg,B组为(102.82±11.75)mmHg,差异无统计学意义(t=0.363,P=0.717);A组的平均动脉压(MAP)为(120.59±11.64)mmHg,B组为(121.03±11.17)mmHg,差异无统计学意义(t=0.191,P=0.849)。治疗后,A组的SBP为(128.69±15.36)mmHg,B组为(137.67±15.92)mmHg,差异有统计学意义(t=2.837,P=0.006);A组的DBP为(80.35±8.57)mmHg,B组为(87.97±8.46)mmHg,差异有统计学意义(t=4.427,P<0.001);A组的MAP为(101.08±9.61)mmHg,B组为(108.18±9.72)mmHg,差异有统计学意义(t=3.632,P=0.001)。A组的不良反应率为5.88%,B组为21.28%,差异有统计学意义(χ^(2)=5.038,P=0.025)。随访1年,A组的终点事件发生率为3.92%,B组为19.15%,差异有统计学意义(χ^(2)=5.692,P=0.017)。结论为EH患者行NEP+Ena治疗可有效降血压,且用药期间的不良反应较少,不易导致远期不良事件,疗效确切。
Objective To analyze the efficacy and safety of nifedipine sustained-release tablets(abbreviated as NFP)and enalapril tablets(abbreviated as Ena)in the treatment of essential hypertension(abbreviated as EH).Methods 98 EH patients were selected who came to the hospital for treatment from January 2018 to February 2019.With the single-double number method as the standard,51 cases in group A were treated with NEP+Ena;47 cases in group B were treated with conventional treatment.Compared the overall efficacy and drug safety.Results The total effective rate of group A was 96.08%,and that of group B was 80.85%,and the difference was statistically significant(χ^(2)=5.692,P=0.017).Before treatment,the systolic blood pressure(abbreviated as SBP)of group A was(162.35±20.65)mmHg,group B was(163.08±20.19)mmHg,and the difference was not statistically significant(t=0.177,P=0.860);the diastolic blood pressure(abbreviated as DBP)of group A was(103.68±11.68)mmHg,group B was(102.82±11.75)mmHg,and the difference was not statistically significant(t=0.363,P=0.717);the mean arterial pressure(referred to as MAP)of group A was(120.59±11.64)mmHg,group B was(121.03±11.17)mmHg,and the difference was not statistically significant(t=0.191,P=0.849).After treatment,the SBP of group A was(128.69±15.36)mmHg,the group B was(137.67±15.92)mmHg,and the difference was statistically significant(t=2.837,P=0.006);the DBP of group A was(80.35±8.57)mmHg,and group B was(87.97±8.46)mmHg,and the difference was statistically significant(t=4.427,P<0.001);the MAP of group A was(101.08±9.61)mmHg,and group B was(108.18±9.72)mmHg,and the difference was statistically significant(t=3.632,P=0.001).The adverse reaction rate of group A was 5.88%,group B was 21.28%,and the difference was statistically significant(χ^(2)=5.038,P=0.025).After 1 year of followup,the end-point event rate was 3.92%in group A and 19.15%in group B,and the difference was statistically significant(χ^(2)=5.692,P=0.017).Conclusion NEP+Ena treatment for EH patients can effectively lower
作者
夏范萍
韩纪林
XIA Fan-ping;HAN Ji-lin(Department of Pharmacy,Laiwu Central Hospital,Xinwen Mining Group,Jinan,Shandong Province,271103 China)
出处
《中外医疗》
2021年第8期115-117,共3页
China & Foreign Medical Treatment
关键词
硝苯地平缓释片
依那普利片
原发性高血压
疗效
安全性
Nifedipine Sustained Release Tablets
Enalapril Tablets
Essential Hypertension
Efficacy
Safety
